@article {Sahajpal2021.07.24.21261046, author = {Nikhil S Sahajpal and Ashis K Mondal and Allan Njau and Zachary Petty and Jiani Chen and Sudha Ananth and Pankaj Ahluwalia and Colin Williams and Ted M Ross and Alka Chaubey and Grace DeSantis and Gary P. Schroth and Justin Bahl and Ravindra Kolhe}, title = {Respiratory Viral Sequencing Panel identifies SARS-CoV-2 variants, transmission and other co-circulating viruses in Georgia, USA: A Diagnostic and Epidemiologic Tool for Mass Surveillance in COVID-19 Pandemic}, elocation-id = {2021.07.24.21261046}, year = {2021}, doi = {10.1101/2021.07.24.21261046}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background In the current phase of COVID-19 pandemic, we are facing two serious public health challenges that include deficits in SARS-CoV-2 variant monitoring, and neglect of other co-circulating respiratory viruses. Additionally, accurate assessment of the evolution, extent and dynamics of the outbreak are required to understand the transmission of the virus amongst seemingly unrelated cases and provide critical epidemiological information. To address these challenges, we evaluated a new high-throughput next-generation sequencing (NGS), respiratory viral panel (RVP) that includes 40 viral pathogens with the aim of analyzing viral subtypes, mutational variants of SARS-CoV-2, model to understand the spread of the virus in the state of Georgia, USA, and to assess other circulating viruses in the same population.Methods This study evaluated a total of 522 samples that included 483 patient samples and 42 synthetic positive control material. The performance metrics were calculated for both clinical and reference control samples by comparing detection results with the RT-PCR assay. The limit of detection (LoD) studies were conducted as per the FDA guidelines. Inference and visualization of the phylogeny of the SARS-CoV-2 sequences were performed through the Nextstrain Command-Line Interface (CLI) tool, utilizing the associated augur and auspice toolkits.Results The performance metrics calculated using both the clinical samples and the reference controls revealed a PPA, NPA and accuracy of 95.98\%, 85.96\% and 94.4\%, respectively. The LoD was determined to be 10 copies/ml with all 25 replicates detected across two different runs. The clade for pangolin lineage B that contains certain distant variants, including P4715L in ORF1ab, Q57H in ORF 3a and, S84L in ORF8 covarying with the D614G spike protein mutation were the most prevalent, early in the pandemic, in Georgia, USA. In our analysis, isolates from the same county formed paraphyletic groups, which indicated virus transmission between counties.Conclusion The study demonstrates the clinical and public health utility of the NGS-RVP to identify novel variants that can provide actionable information to prevent or mitigate emerging viral threats, models that provide insights into viral transmission patterns and predict transmission/ resurgence of regional outbreaks and provide critical information on co-circulating respiratory viruses that might be independent factors contributing to the global disease burden.Competing Interest StatementRK has received honoraria, travel funding, and research support from Illumina, Asuragen, Bionano, PerkinElmer Inc., QIAGEN, and BMS. AC is salaried employee of Bionano Genomics Inc. GD and GPS are salaried employee of Illumina Inc.Funding StatementThis project has been funded by the National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services, under contract 75N93019C00052, and NIH CEIRS contracts HHSN272201400006C and HHSN27220140000; CDC contract 75D30121C10133Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The samples were processed under an approved HAC by the IRB Committee A (IRB registration $\#$ 611298), Augusta University, GA. Based on the IRB approval, the need for consent was waived, all PHI was removed and the data was anonymized before accessing for the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is made available within the manuscript.}, URL = {https://www.medrxiv.org/content/early/2021/07/26/2021.07.24.21261046}, eprint = {https://www.medrxiv.org/content/early/2021/07/26/2021.07.24.21261046.full.pdf}, journal = {medRxiv} }